In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Vir Biotechnology's current price exceeds the PERT-weighted fair value by 22.9%, indicating potential overvaluation based on multiple valuation methods, especially a negative DCF midpoint. High liquidity and leverage contrast with zero profitability and efficiency scores, highlighting financial vulnerability. Analyst targets suggest optimism, yet downside risk appears minimal, signaling price stability despite fundamental concerns.